X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs NATCO PHARMA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD NATCO PHARMA LUPIN LTD/
NATCO PHARMA
 
P/E (TTM) x 29.5 16.9 174.3% View Chart
P/BV x 3.1 18.3 16.9% View Chart
Dividend Yield % 0.5 0.6 85.8%  

Financials

 LUPIN LTD   NATCO PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
NATCO PHARMA
Mar-14
LUPIN LTD/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,465877 167.0%   
Low Rs727424 171.7%   
Sales per share (Unadj.) Rs349.6223.4 156.5%  
Earnings per share (Unadj.) Rs5.631.1 17.9%  
Cash flow per share (Unadj.) Rs29.640.3 73.4%  
Dividends per share (Unadj.) Rs5.005.00 100.0%  
Dividend yield (eoy) %0.50.8 59.3%  
Book value per share (Unadj.) Rs300.3219.5 136.8%  
Shares outstanding (eoy) m452.0833.07 1,367.0%   
Bonus/Rights/Conversions ESOPSPA-  
Price / Sales ratio x3.12.9 107.7%   
Avg P/E ratio x197.220.9 942.2%  
P/CF ratio (eoy) x37.116.1 229.5%  
Price / Book Value ratio x3.63.0 123.2%  
Dividend payout %90.016.1 559.0%   
Avg Mkt Cap Rs m495,50221,504 2,304.3%   
No. of employees `00017.0NA-   
Total wages/salary Rs m28,6471,128 2,540.3%   
Avg. sales/employee Rs Th9,273.6NM-  
Avg. wages/employee Rs Th1,681.0NM-  
Avg. net profit/employee Rs Th147.4NM-  
INCOME DATA
Net Sales Rs m158,0427,389 2,138.9%  
Other income Rs m1,504167 899.8%   
Total revenues Rs m159,5457,556 2,111.5%   
Gross profit Rs m31,4751,793 1,755.1%  
Depreciation Rs m10,859304 3,567.2%   
Interest Rs m2,044366 558.0%   
Profit before tax Rs m20,0761,290 1,556.6%   
Minority Interest Rs m-7146 -153.1%   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,6440-   
Tax Rs m2,885309 934.4%   
Profit after tax Rs m2,5131,027 244.6%  
Gross profit margin %19.924.3 82.1%  
Effective tax rate %14.423.9 60.0%   
Net profit margin %1.613.9 11.4%  
BALANCE SHEET DATA
Current assets Rs m122,0953,681 3,316.6%   
Current liabilities Rs m50,9563,123 1,631.7%   
Net working cap to sales %45.07.6 595.5%  
Current ratio x2.41.2 203.3%  
Inventory Days Days8589 94.5%  
Debtors Days Days12059 204.3%  
Net fixed assets Rs m129,8767,685 1,690.0%   
Share capital Rs m904331 273.4%   
"Free" reserves Rs m134,8666,670 2,022.0%   
Net worth Rs m135,7717,259 1,870.4%   
Long term debt Rs m64,245955 6,727.9%   
Total assets Rs m263,05411,957 2,200.0%  
Interest coverage x10.84.5 239.4%   
Debt to equity ratio x0.50.1 359.7%  
Sales to assets ratio x0.60.6 97.2%   
Return on assets %1.711.7 14.9%  
Return on equity %1.914.2 13.1%  
Return on capital %3.720.7 17.9%  
Exports to sales %039.4 0.0%   
Imports to sales %05.7 0.0%   
Exports (fob) Rs mNA2,908 0.0%   
Imports (cif) Rs mNA421 0.0%   
Fx inflow Rs m53,1413,445 1,542.4%   
Fx outflow Rs m19,335703 2,751.1%   
Net fx Rs m33,8072,743 1,232.6%   
CASH FLOW
From Operations Rs m17,5121,440 1,215.9%  
From Investments Rs m-14,073-1,089 1,292.0%  
From Financial Activity Rs m-14,921-353 4,230.5%  
Net Cashflow Rs m-11,482-1 770,583.9%  

Share Holding

Indian Promoters % 46.6 52.0 89.5%  
Foreign collaborators % 0.2 1.5 13.6%  
Indian inst/Mut Fund % 11.3 7.8 144.1%  
FIIs % 31.9 16.6 191.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 26.0 38.8%  
Shareholders   98,259 25,395 386.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   STRIDES SHASUN LTD  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare LUPIN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Sep 18, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE LUPIN LTD WITH

MARKET STATS